J Christian Virchow, Oliver Pfaar, Marek Lommatzsch
{"title":"Allergen immunotherapy for allergic asthma.","authors":"J Christian Virchow, Oliver Pfaar, Marek Lommatzsch","doi":"10.5414/ALX02451E","DOIUrl":null,"url":null,"abstract":"<p><p>Remission is the goal of modern asthma treatment. Allergen immunotherapy (AIT) is an essential component in the armamentarium of personalized asthma therapy. Subcutaneous AIT (SCIT) or sublingual AIT (SLIT) offer the possibility to prevent asthma in patients with allergic rhinitis (reduction of the risk of developing asthma) and the possibility to achieve remission in patients with allergic asthma. Accordingly, AIT should always be considered in patients with asthma and a documented, clinically relevant allergy. However, precise phenotyping of the patient is an essential prerequisite for a success of AIT in asthma.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"6-11"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02451E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Remission is the goal of modern asthma treatment. Allergen immunotherapy (AIT) is an essential component in the armamentarium of personalized asthma therapy. Subcutaneous AIT (SCIT) or sublingual AIT (SLIT) offer the possibility to prevent asthma in patients with allergic rhinitis (reduction of the risk of developing asthma) and the possibility to achieve remission in patients with allergic asthma. Accordingly, AIT should always be considered in patients with asthma and a documented, clinically relevant allergy. However, precise phenotyping of the patient is an essential prerequisite for a success of AIT in asthma.
缓解是现代哮喘治疗的目标。过敏原免疫疗法（AIT）是个性化哮喘疗法的重要组成部分。皮下注射过敏原免疫疗法（SCIT）或舌下注射过敏原免疫疗法（SLIT）可预防过敏性鼻炎患者的哮喘（降低哮喘发病风险），并可缓解过敏性哮喘患者的病情。因此，对于患有哮喘并有临床相关过敏记录的患者，应始终考虑使用 AIT。然而，对患者进行精确的表型分析是 AIT 成功治疗哮喘的必要前提。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
